Coronary Heart Disease
Conditions
Interventions
Alirocumab Group:Alirocumab
Control Group:None
Sponsors
The Third Affiliated Hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Agree to be included in the study; 2. No gender limit, patients aged over 18 years; 3. Patients with coronary heart disease who plan to receive elective coronary angiography to identify coronary artery lesions and further undergo PCI implantation of drug-eluting stents; 4. Baseline LDL-C level above 3.4mmol/L (130mg/dl); 5. Patients meet one of the following criteria of (1) and (2) +one of the following criteria of (3), (4), (5), (6), (7) and (8) : (1) The patient underwent coronary CTA or coronary angiography in the past, indicating that one or more vessels of the main branch (anterior descending branch, circumflex branch, right coronary artery) or branches (diagonal branch, OM branch, PLA branch, PDA branch) were more than 70% stenosis; (2) The patient had angina pectoris, which met at least two of the following three characteristics: retrosternal discomfort, characterized by its nature and duration; Fatigue or emotional stress can be induced; Relief within minutes after rest and/or treatment with nitrates; (3) With diabetes; (4) Suffering from high blood pressure; (5) Have hyperlipidemia, including total cholesterol >=6.2mmol/L or LDL-C>=4.1mmol/L; (6) A long history of smoking; (7) Obesity, BMI>=28kg/m^2; (8) Family history of early onset cardiovascular disease, defined as first-degree relatives with coronary heart disease < 55 years old in males and < 65 years old in females.
Exclusion criteria
Exclusion criteria: 1. Acute myocardial infarction in the last 3 months; 2. Preoperative troponin was higher than the normal value; 3. Moderate to severe liver dysfunction (ALT or AST> 2 times the upper limit of normal); 4. Severe renal impairment (creatinine clearance <30 ml/min); 5. Severe anemia (hemoglobin <60g/L); 6. Patients who do not wish to use any contraceptive measures during pregnancy, lactation and preparation for pregnancy; 7. Patients who did not want to receive aliciumab for 3 months; 8. No stent was implanted.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cardiac troponin; | — |
Countries
China
Contacts
Public ContactLiu Jinlai
The Third Affiliated Hospital, Sun Yat-sen University
Outcome results
None listed